Nutriband (9WV) AI Stock Analysis

0 Followers

Nutriband

(Frankfurt:9WV)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Business Model StrengthNutriband's focus on transdermal drug delivery systems offers a unique value proposition in healthcare, enhancing patient compliance and therapeutic outcomes.

Negative Factors

Profitability ChallengesOngoing operational losses and negative cash flows indicate difficulty in achieving profitability, impacting long-term business sustainability.

Nutriband (9WV) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 72.20M
Dividend Yield: ―
Average Volume (3M): 254
Price to Earnings (P/E): -10.4
Beta (1Y): 0.75
Revenue Growth: -41.08%
EPS Growth: 80.63%
Country: Germany
Employees: 13
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Nutriband Business Overview & Revenue Model

Company Description

Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abu...

Nutriband Risk Analysis

Nutriband disclosed 36 risk factors in its most recent earnings report. Nutriband reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.Because we are an early-stage company with minimal revenue and a history of losses and we expect to continue to incur losses for the foreseeable future, we cannot assure you that we can or will be able to operate profitably.Q3, 2024

Nutriband Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:9WV against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CSBR	48Neutral	$66.11M	-60.51	-27.88%	―	6.65%	-136.61%
ALXO	42Neutral	$153.49M	-0.99	-90.30%	―	―	48.20%
ADAG	39Underperform	$137.64M	-4.51	-29.09%	―	8906.15%	41.48%
IFRX	39Underperform	$178.32M	-3.27	-31.81%	―	―	―
PLRX	37Underperform	$48.65M	-0.52	-53.22%	―	―	55.84%

* Healthcare Sector Average

Performance Comparison

DE:9WV and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:9WV	Nutriband	4.98	0.22	4.62%
CSBR	Champions Oncology	4.78	-2.12	-30.72%
IFRX	Inflarx N.V.	1.18	-0.09	-7.09%
PLRX	Pliant Therapeutics, Inc.	0.78	-0.94	-54.83%
ALXO	Alx Oncology Holdings, Inc.	1.12	-0.10	-8.20%
ADAG	Adagene, Inc.	2.13	0.33	18.33%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Nutriband AI Stock Analysis